new glp-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity What do the new 'GLP-1
Description
Feb 8, 2026 You are wasting money
What we are seeing now is their additional benefit for treating obesity as a metabolic disease, not just a number on the scale
For patients who need a meaningful, evidence-based metabolic interventiona need supported by chronic disease guidelines from the Centers for Disease Control and Prevention (CDC)but have been unwilling or unable to engage with injectables, this pill changes the conversation
doi:10.1152/ajpendo.00642.2020 83
[DOI] [PMC free article] [PubMed] [Google Scholar] 68.Ambudkar I.S
doi: 10.1016/j.physbeh.2016.03.016 227 WangYChenSXuZChenSYaoWGaoX
